CYTK Cytokinetics Inc

Price (delayed)

$70.11

Market cap

$7.22B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.45

Enterprise value

$7.86B

Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by ...

Highlights
CYTK's equity is up by 12% since the previous quarter
Cytokinetics's gross profit has plunged by 92% YoY and by 3.6% from the previous quarter
The revenue has dropped by 92% year-on-year and by 3.6% since the previous quarter

Key stats

What are the main financial stats of CYTK
Market
Shares outstanding
103M
Market cap
$7.22B
Enterprise value
$7.86B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
898.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,044.41
Earnings
Revenue
$7.53M
EBIT
-$497.94M
EBITDA
-$486.05M
Free cash flow
-$415.75M
Per share
EPS
-$5.45
Free cash flow per share
-$4.31
Book value per share
-$3.94
Revenue per share
$0.08
TBVPS
$8.54
Balance sheet
Total assets
$824.32M
Total liabilities
$1.21B
Debt
$755.77M
Equity
-$386.32M
Working capital
$525.37M
Liquidity
Debt to equity
-1.96
Current ratio
6.12
Quick ratio
6
Net debt/EBITDA
-1.32
Margins
EBITDA margin
-6,454.8%
Gross margin
100%
Net margin
-6,988.6%
Operating margin
-6,589.7%
Efficiency
Return on assets
-65.1%
Return on equity
N/A
Return on invested capital
-36%
Return on capital employed
-69%
Return on sales
-6,612.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CYTK stock price

How has the Cytokinetics stock price performed over time
Intraday
-1.82%
1 week
6.18%
1 month
-4.08%
1 year
100.43%
YTD
-16.03%
QTD
-16.03%

Financial performance

How have Cytokinetics's revenue and profit performed over time
Revenue
$7.53M
Gross profit
$7.53M
Operating income
-$496.21M
Net income
-$526.24M
Gross margin
100%
Net margin
-6,988.6%
Cytokinetics's gross profit has plunged by 92% YoY and by 3.6% from the previous quarter
The revenue has dropped by 92% year-on-year and by 3.6% since the previous quarter
Cytokinetics's operating income has plunged by 53% YoY
The net income is down by 35% year-on-year

Growth

What is Cytokinetics's growth rate over time

Valuation

What is Cytokinetics stock price valuation
P/E
N/A
P/B
N/A
P/S
898.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,044.41
The EPS has contracted by 26% YoY
CYTK's equity is up by 12% since the previous quarter
CYTK's P/S is 102% above its last 4 quarters average of 445.1
The revenue has dropped by 92% year-on-year and by 3.6% since the previous quarter

Efficiency

How efficient is Cytokinetics business performance
The company's return on assets has shrunk by 56% YoY and by 6% QoQ
CYTK's return on invested capital is down by 26% year-on-year and by 4.3% since the previous quarter
The ROS has contracted by 3.7% from the previous quarter

Dividends

What is CYTK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CYTK.

Financial health

How did Cytokinetics financials performed over time
The total assets is 32% smaller than the total liabilities
The company's current ratio fell by 35% YoY and by 15% QoQ
Cytokinetics's quick ratio has decreased by 35% YoY and by 14% from the previous quarter
Cytokinetics's debt to equity has surged by 72% YoY but it has decreased by 15% QoQ
CYTK's equity is up by 12% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.